Facts & Figures

554
Organizations
37595
Employees
12.2 bn
Sales / Year
4602
Publications
Source: Vienna Life Science Report 2017/18 (Data: 2017) More Information

Are you up to date?

News

Uni Vienna: Empathic birds

Raven observers show emotional contagion with raven demonstrators experiencing an unpleasant affect

MedUni Vienna: Ebola: global network including MedUni Vienna draws up Public Health models for better understanding of epidemics

The tenth Ebola outbreak since the emergence of this virus is now shaking the Congo. The Health Ministry of this central...

AstraZeneca’s PrimeTime: Der Preis des Menschen, sein Wert und seine Würde

Konrad Paul Liessmann geht der Frage, was ein Menschenleben kostet in seinem Vortrag im Rahmen der PrimeTime...

All news

Driven by curiosity, inspired by our city...

Twitter @lifesciencevie

Events

28.5. - 29.5.2019
International meeting

Vienna

dHealth 2019

13th Annual Conference on Health Informatics meets Digital Health "From eHealth to dHealth"

LISAvienna event

Vienna

BI Office Hours in Vienna

In collaboration with LISAvienna, Boehringer Ingelheim invites the regional biomedical community to join personalized...

3.6. - 6.6.2019
International meeting

Philadelphia

BIO International Convention

It starts with one... Advances in biotech begin with one meeting, one theory, one trial, one breakthrough. You make it...

Wien

MedUni Wien: Eröffnung des Klinischen Labors für Bionische Extremitätenrekonstruktion

Innovative rekonstruktive Ansätze zu Wiederherstellungsmöglichkeiten an der Grenze zwischen Mensch und Maschine

All events

Why Vienna?

Philipp von Lattorff - Boehringer Ingelheim
(C) Boehringer Ingelheim / Marion Carniel

Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.

Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG